Wegovy, including the new HD 7.2 mg dose, anchors Novo's obesity sales. Resolves YES if Novo reports full-year 2026 Wegovy revenue above DKK-equivalent US$10 billion. Source: Novo Nordisk annual report.
Market open
Jun 15, 2026, 03:26 p.m.
Market closes
Feb 10, 2027, 02:26 p.m.
Projected payout
After market closes
